NO3090119T3 - - Google Patents

Info

Publication number
NO3090119T3
NO3090119T3 NO14823980A NO14823980A NO3090119T3 NO 3090119 T3 NO3090119 T3 NO 3090119T3 NO 14823980 A NO14823980 A NO 14823980A NO 14823980 A NO14823980 A NO 14823980A NO 3090119 T3 NO3090119 T3 NO 3090119T3
Authority
NO
Norway
Application number
NO14823980A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3090119(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3090119T3 publication Critical patent/NO3090119T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO14823980A 2013-03-14 2014-12-19 NO3090119T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
NO3090119T3 true NO3090119T3 (enExample) 2018-03-31

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14823980A NO3090119T3 (enExample) 2013-03-14 2014-12-19

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR20180045055A (enExample)
CN (3) CN109908353A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TWI678205B (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
CN105658219A (zh) * 2013-10-25 2016-06-08 艾伯维公司 用于治疗hcv的方法
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
CA2943054A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3383662B1 (en) 2016-01-08 2020-09-02 Entrust Datacard Corporation Card printing mechanism with card return path
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
MA46292A (fr) * 2016-09-23 2019-07-31 Abbvie Inc Réglage de dose
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CN112351799A (zh) * 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522862A (ja) * 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Also Published As

Publication number Publication date
JP6563894B2 (ja) 2019-08-21
CY1121474T1 (el) 2020-05-29
PL2968302T3 (pl) 2018-04-30
WO2014152635A9 (en) 2014-12-11
EP3318258B1 (en) 2020-05-13
CA2901818C (en) 2021-05-04
EP2968302A1 (en) 2016-01-20
LT2968302T (lt) 2017-12-27
EP3733180A1 (en) 2020-11-04
IL267927A (en) 2019-09-26
SG11201507361YA (en) 2015-10-29
SG10201709840UA (en) 2018-01-30
WO2014152635A1 (en) 2014-09-25
EP2968302B1 (en) 2017-09-06
TW202002979A (zh) 2020-01-16
CN109908353A (zh) 2019-06-21
DK2968302T3 (en) 2017-12-18
ZA201705080B (en) 2019-02-27
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
EA201890507A1 (ru) 2018-07-31
MX2015012536A (es) 2016-01-12
HUE036069T2 (hu) 2018-06-28
CN108187056A (zh) 2018-06-22
CN105007921B (zh) 2018-12-11
KR20180045055A (ko) 2018-05-03
JP2019167347A (ja) 2019-10-03
HK1213191A1 (en) 2016-06-30
EA030482B1 (ru) 2018-08-31
US20140274934A1 (en) 2014-09-18
JP2019214585A (ja) 2019-12-19
AU2018202581A1 (en) 2018-05-10
AU2020201656A1 (en) 2020-03-26
HRP20171898T1 (hr) 2018-04-06
RS56735B1 (sr) 2018-03-30
BR112015020918A2 (pt) 2017-07-18
IL240445A0 (en) 2015-09-24
JP2016513703A (ja) 2016-05-16
AU2014239322A1 (en) 2015-08-27
SMT201800017T1 (it) 2018-03-08
IL240445B (en) 2019-07-31
KR101853605B1 (ko) 2018-05-03
EA201591701A1 (ru) 2016-02-29
EP3318258A1 (en) 2018-05-09
CN105007921A (zh) 2015-10-28
PL2968302T4 (pl) 2018-04-30
TW201505633A (zh) 2015-02-16
KR20150129035A (ko) 2015-11-18
CA2901818A1 (en) 2014-09-25
AU2014239322B2 (en) 2018-04-05
SI2968302T1 (en) 2018-04-30
AU2018202581B2 (en) 2019-12-05
EP3915559A1 (en) 2021-12-01
EP2968302B9 (en) 2019-02-13
ES2654109T3 (es) 2018-02-12
HK1255257A1 (en) 2019-08-09

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR112016011826A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014018502A2 (enExample)
BR112014019326A2 (enExample)
BR112014018516A2 (enExample)
BR112016000870A2 (enExample)
BR112014017765A2 (enExample)
BR112014018480A2 (enExample)
BR112014020341A2 (enExample)
BR112014017669A2 (enExample)
BR112014021878A2 (enExample)
BR112016005529A2 (enExample)
BR112014018207A2 (enExample)
BR112014019204A2 (enExample)
BR112014017901A2 (enExample)
BR112016010801A2 (enExample)
BR112016009125A2 (enExample)
BR112014017745A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112016003282A2 (enExample)